COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

79 results for "Cancer" and "Endocrine Cancers"

An Open-Label, Phase 1 Study Of KHK2455 In Combination With Avelumab In Adult Subjects With Locally Advanced Or Metastatic Urothelial Carcinoma

The main purposes of this study are to:
1. Test and study the side effects (to determine the safety) of KHK2455 when taken in combination with avelumab; and
2. Identify the highest dose of KHK2455 that can be given and safely tolerated in combination with avelumab.
Protocol No
KYOWA-2455-002
Sub Category
Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1, Open-Label Study In Two Parts, Evaluating The Safety, Tolerability, Pharmacokinetics, And Clinical Activity Of CCW702 In Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma

The purpose of the study is to assess the safety, tolerability, the time course of the drug in your body known as pharmacokinetics, and the observed effects produced by the drug called pharmacodynamics of CCW702 (study drug) when given as an injection under your skin (subcutaneous injection) every other day for two weeks for a total of 6 doses in a twenty-eight (28) day cycle of dosing in patients like yourself who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
Protocol No
CALIBR-CBR-CCW702-3001
Sub Category
Early Phase/Multiple Disease Site Cancers

Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors

This study is being done for the following purposes:
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
Protocol No
TRISHULA-TTX-030-002
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Prostate and Urologic Cancers, Head and Neck Cancers

A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer

The purpose of this study is to evaluate in patients with metastatic pancreatic cancer, the overall safety, tolerability, and preliminary anti-tumor activity of adding an investigational drug, L DOS47, to doxorubicin, a type of chemotherapy drug
Protocol No
HELIX-LDOS006
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Phase 3 Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in mCRPC
Protocol No
MERCK-MK-7339-010
Sub Category
Prostate and Urologic Cancers

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Protocol No
ALLIANCE-A031102
Sub Category
Prostate and Urologic Cancers

A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to find the best dose of WVT078 or WVT078 combined with WHG626 that can be given to patients with multiple myeloma and to evaluate how well the treatment might work in treating patients with this type of cancer. This is the first time WVT078 or WVT078 combined with WHG626 are being used in humans. WHG626 has been studied previously in patients with different types of cancer than yours
Protocol No
NOVARTIS-CWVT078A12101
Sub Category
Early Phase/Multiple Disease Site Cancers

A Phase 1b Trial of Magrolimab Monotherapy Or Magrolimab In Combination With Azacitidine In Patients With Hematological Malignancies

The purpose of this study is to test the safety of Hu5F9-G4 alone, or in combination with azacitidine in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Other purposes of this study are to determine the best dose of Hu5F9-G4, the quantity of Hu5F9-G4 in your blood, the side effects it has on your body, and whether or not it can improve your cancer.
Protocol No
FORTYSEVEN-5F9005
Sub Category
Early Phase/Multiple Disease Site Cancers

A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

The purpose of this clinical research study is to identify an appropriate safe dose of JBH492 that can be given to patients with NHL or CLL who did not improve after treatment with currently available therapies, have had their disease worsen, and/or cannot tolerate currently available therapies. This study will also evaluate how well JBH492 might work in treating your disease and will give us an understanding how your body responds to the study treatment. In order to achieve this, a number of blood and tissue samples will be collected during the study.
Protocol No
NOVARTIS-CJBH492A12101
Sub Category
Early Phase/Multiple Disease Site Cancers

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

The purpose of this study is to find a safe and tolerable dose of either JNJ-64407564 [anti-GPRC5DxCD3] or JNJ-64007957 [anti-BCMAxCD3] when administered in combination with Daratumumab subcutaneous injection (Dara SC) in patients with multiple myeloma. A dose is how much of a drug you take at one time. This study will also look at how JNJ-64407564 [anti-GPRC5DxCD3] and Dara SC, known as combination 1 or JNJ-64007957 [anti-BCMAxCD3] and Dara SC, known as combination 2 act in your body, as well as whether each of the combination of drugs will treat your multiple myeloma.

1. Combination 1: JNJ-64407564 [anti-GPRC5DxCD3] and Dara SC
2. Combination 2: JNJ-64007957 [anti-BCMAxCD3] and Dara SC

Another purpose of this study is to find out how long JNJ-64407564 [anti-GPRC5DxCD3] or JNJ-64007957 [anti-BCMAxCD3] in combination with Dara SC stay in and act on your body. This is measured by blood tests.
Protocol No
JANSSEN-64407564MMY1002
Sub Category
Early Phase/Multiple Disease Site Cancers